Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache

PHASE3RecruitingINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Cluster Headache
Interventions
DRUG

Botulinum toxin type A

Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)

DRUG

placebo

0.5 ml Sodium Chloride (NaCl) 0.9% Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)

Trial Locations (5)

Unknown

RECRUITING

Praxisklinik Ulmenhof, Hamburg

RECRUITING

Fondazione IRCCS Istituto Neurologico Carlo Besta (CBNI), Milan

RECRUITING

St Olavs Hospital, Trondheim

RECRUITING

Department of Neurology, University Clinic Hospital. Catholic University of Valencia, Valencia

RECRUITING

National Hospital of Neurology and Neurosurgery, University College of London, London

All Listed Sponsors
collaborator

St. Olavs Hospital

OTHER

collaborator

University College, London

OTHER

collaborator

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

OTHER

collaborator

Catholic University of Valencia

OTHER

collaborator

PRAXISKLINIK ULMENHOF

UNKNOWN

lead

Norwegian University of Science and Technology

OTHER

NCT03944876 - Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache | Biotech Hunter | Biotech Hunter